

**REXEED™ - A**  
Performance (in vitro)

	REXEED-13A			REXEED-15A			REXEED-18A			REXEED-21A			REXEED-25A		
Blood Flow (mL/min)	200	300	400	200	300	400	200	300	400	200	300	400	200	300	400
Clearances (mL/min)															
Urea	194	264	306	196	272	317	198	280	330	199	284	340	199	287	350
Creatinine	188	247	284	191	255	296	194	265	309	195	272	317	196	280	330
Phosphate	180	227	259	185	238	272	190	250	289	192	257	299	194	260	303
Vitamin B <sub>12</sub>	133	155	165	142	168	179	152	183	197	160	194	212	163	199	225
Inulin (Qb=200mL/min)	78			87			92			102			117		
KoA (Urea) (mL/min)	1027			1190			1415			1569			1714		
KUF (mL/hr/mmHg (mL/hr/kPa))	66 (495)			72 (540)			81 (608)			90 (675)			102 (773)		
Effective Surface Area (m <sup>2</sup> )	1.3			1.5			1.8			2.1			2.5		
Sieving Coefficient															
Inulin							1.0								
β <sub>2</sub> -microglobulin							0.8								
Myoglobin							0.4								
Albumin							0.001								

**Conditions:** Clearances: Qd=500mL/min, Qf=0mL/min KoA: Qb=300mL/min, Qd=500mL/min, Qf=0mL/min  
KUF: Measured with bovine blood, TP=60±5g/L, Hct=32±2%, Qb=300mL/min  
ISO8637: 2004

Specifications

	REXEED-13A	REXEED-15A	REXEED-18A	REXEED-21A	REXEED-25A
Membrane	REXBRANE™ (Asahi Polysulfone)				
Internal Diameter of Hollow Fiber (μm)	185				
Wall Thickness of Hollow Fiber (μm)	45				
Priming Volume (mL)	76	86	103	117	137
Maximum TMP (mmHg (kPa))	500 (66)				
Maximum Blood Flow (mL/min)	500				
Maximum Dialysate Flow (ml/min)	800				
Dimensions (mm [L] x mm [D])	334 x 38	334 x 41	334 x 43	334 x 47	334 x 50
Weight (g)	412	463	520	604	675
Sterilization	Gamma-Ray				

Note: High permeability devices. Use only with ultrafiltration controlling equipment. ISO8637: 2004

**AsahiKASEI**

**Manufacturer:**  
**ASAHI KASEI MEDICAL CO., LTD.**  
1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101 Japan  
TEL: +81-3-3296-3727 FAX: +81-3-3296-3722  
URL: <http://www.asahikasei-medical.com>

**Represented in Europe by:**  
**ASAHI KASEI MEDICAL EUROPE GmbH**  
Herriotstrasse 1, 60528 Frankfurt am Main, Germany  
TEL: +49 (0) 69 66 37 15 00 FAX: +49 (0) 69 6 66 51 93


**Represented in Americas by:**  
**ASAHI KASEI MEDICAL AMERICA INC.**  
3570 Winchester Road, Suite 103, Memphis, Tennessee 38118, USA  
TEL: +1-888-362-6105

CE  
0086

Copyright © 2013 Asahi Kasei Medical Co., Ltd. Printed in Japan No.2013.4-7793


**AsahiKASEI**

Exceed Your Expectations





**HEMODIALYZER**  
**REXEED™**  
**REXBRANE™**

**ASAHI KASEI MEDICAL CO., LTD.**  
A Pioneer in Blood Purification




## Dialysate Flow & Penetration

Dye was injected into the dialysate inlet port, with dialysate flow at 500 mL/min, then 10mL fractions were collected at the outlet port and measured for dye concentration by absorbance.



A sharp, symmetrical peak indicates rapid and complete penetration of dye into the center of the fiber bundle to give uniform flow distribution, proving the benefits of fiber bundle and housing design optimization.


## Clinical Evaluation of REXEED-A and Other PS



Good phosphate management, particularly in higher body weight patients is afforded by the superior clearance characteristics of REXEED-A.

Maurizi J. et al., CHU (University Hospital Center) Michallon, Grenoble, France, In vivo Clinical Evaluation, 2005.


## Clinical Evaluation of REXEED-A and PES



REXEED-A has high removal for small toxins as well as excellent reduction rates for low molecular weight proteins such as β<sub>2</sub>-MG (M.W. 11,800). The sharp membrane cut-off minimizes albumin loss.

Adapted from: S. Osawa, H. Yamamoto, S. Hisajima, "Evaluation of dialyzers with various characteristics", *Am J High Performance Membrane '95: Kidney & Dial. Suppl.* 59: 215-219, 2005.

## Pre - Dialysis Creatinine



Three high body mass patients were changed from their original high flux polysulfone dialyzers (2.2m<sup>2</sup>) to REXEED-25A and dialyzed for 4 weeks. Dialysis conditions were unchanged during the evaluation period, after which the patients were returned to their original dialyzers.

Lindley E.J. et al., Leeds Teaching Hospitals NHS Trust, Leeds, UK. In vivo Clinical Evaluation, 2005.